IRADIMED CORP IRMD
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
6/9
Piotroski F — financial health
14.84
Altman Z″ — distress risk · safe
66.9%
Dividend payout · stretched
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $83.8M | $22.5M | $64.3M | $17.2M | $94.6M |
| 2024 | $73.2M | $19.2M | $56.4M | $17.6M | $86.8M |
| 2023 | $65.6M | $17.2M | $50.2M | $6.0M | $71.4M |
| 2022 | $53.3M | $12.8M | $41.3M | $9.2M | $73.7M |
| 2021 | $41.8M | $9.3M | $32.0M | $10.8M | $72.2M |
| 2020 | $31.7M | $1.4M | $23.6M | $5.4M | $61.4M |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 14.84 (safe)
- Working capital / assets 0.653
- Retained earnings / assets 0.59
- EBIT / assets 0.24
- Equity / liabilities 6.683
Source: SEC EDGAR filings · CIK 0001325618 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.